Drug Trial Radar · NCT05585645
A Study to Compare Efficacy and Safety of Nanogen's Darbepoetin Alfa With Aranesp® (Amgen) in the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis (CKD)
Last checked: Nov 20, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
214
Actual
Start
Aug 8, 2019
Primary completion
Nov 23, 2022
Study completion Nov 23, 2022
Sponsor
- Lead sponsor
- Nanogen Pharmaceutical Biotechnology Joint Stock CompanyIndustry
- Sponsor type
- Industry
- Collaborators
- Vietstar Biomedical Research; MEDPHASE CLINICAL RESEARCH CONSULTANT COMPANY LIMITED; CLINICAL RESEARCH VIET NAM SKILL TRAINING AND CONSULTING COMPANY LIMITED; MedProve Inc
- First posted
- Oct 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a double-blind, two-arm, randomized, multicenter to compare the efficacy and safety of NNG-DEPO and Aranesp in CKD on dialysis patients. Patients aged 18 to 65 years (inclusive), diagnosed with anemia due to CKD in dialysis, who meet all inclusion criteria, requiring treatment with Darbepoetin alfa. The study subjects (patients) will be randomized into a 1:1 ratio to NNG-DEPO and Aranesp treatment arms respectively. Patients will receive either NNG-DEPO or Aranesp 0.75 µg/kg by subcutaneous injection every other week for 24 weeks. During the treatment, dose adjustments will be made as necessary to achieve a hemoglobin response, defined as maintaining Hb in the target range of 10 - 12 g/dL.
Conditions
- Anemia
- Chronic Kidney Disease Requiring Chronic Dialysis
Interventions
Stimus (NNG-DEPO)Biological
Nanogen's Darbepoetin alfa 10µg/0.4mL, 20µg/0.5mL, 40µg/0.4mL, 60µg/0.3mL, prefilled syringe
Primary outcomes
What the sponsor says the trial is designed to measure.
- The mean change Hemoglobin level from baseline to Week 24Time frame: Week 0 (Assessed predose)- Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
NANOGEN Pharmaceutical Biotechnology JSC
Ho Chi Minh City, Vietnam
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.